一分钟看懂
这是一项关于鼻咽癌的II 期研究，登记的药物或干预包括CT-guided percutaneous local ablation；Gemcitabine；Cisplatin；PD-1 inhibitor，当前状态为尚未开始招募。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
CT-guided percutaneous local ablation；Gemcitabine；Cisplatin；PD-1 inhibitor · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-sen University Cancer Center · 广州
公开的入选条件
- * Written informed consent to participate in the trial
- * Age 18 to 75 years, any sex
- * Histologically or cytologically confirmed nasopharyngeal carcinoma, with clinically diagnosed liver and/or lung metastases
- * Primary nasopharyngeal tumor cured after curative treatment, with no lymph node metastasis and no metastases outside the liver and lung (metachronous metastasis: distant metastasis detected at least 6 months after curative treatment of the primary tumor)
- * No more than 5 liver and/or lung metastases, each 3 cm or smaller in diameter
- * Liver and/or lung metastases amenable to ablation
- * ECOG performance status 0 or 1
- * Adequate hematologic and organ function: absolute neutrophil count ≥1.5×10\^9/L; hemoglobin ≥70 g/L; platelet count ≥50×10\^9/L; white blood cell count ≥3.0×10\^9/L; serum albumin ≥28 g/L; total bilirubin ≤3.0 mg/dL; AST and ALT ≤5×ULN; serum creatinine ≤1.5
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07824856；登记信息更新于 2026-09-17。